Maryam Majidinia

Maryam Majidinia

Auto-generated profile, based on publicly available information

Maryam Majidinia

Solid Tumor Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2017 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MMMaryam Majidinia
Maryam Majidinia
ASAlireza Sadeghpour
Alireza Sadeghpour
BYBahman Yousefi
Bahman Yousefi

1 December 2019 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Open access
SSSaeid Safiri
Saeid Safiri
SSSadaf G Sepanlou
Sadaf G Sepanlou
KIKevin S Ikuta
Kevin S Ikuta
CBCatherine Bisignano
Catherine Bisignano
HSHamideh Salimzadeh
Hamideh Salimzadeh
RMReza Malekzadeh
Reza Malekzadeh
Data about the global, regional, and country-specific variations in the levels and trends of colorectal cancer are required to understand the impact of this disease and the trends in its burden to help policy makers allocate resources. Here we provide a status report on the incidence, mortality, and disability caused by colorectal cancer in 195 countries and territories between 1990 and 2017. Vital registration, sample vital registration, verbal autopsy, and cancer registry data were used to generate incidence, death, and disability-adjusted life-year (DALY) estimates of colorectal cancer at the global, regional, and national levels. We also determined the association between development levels and colorectal cancer age-standardised DALY rates, and calculated DALYs attributable to risk factors that had evidence of causation with colorectal cancer. All of the estimates are reported as counts and age-standardised rates per 100 000 person-years, with some estimates also presented by sex and 5-year age groups. In 2017, there were 1·8 million (95% UI 1·8-1·9) incident cases of colorectal cancer globally, with an age-standardised incidence rate of 23·2 (22·7-23·7) per 100 000 person-years that increased by 9·5% (4·5-13·5) between 1990 and 2017. Globally, colorectal cancer accounted for 896 000 (876 300-915 700) deaths in 2017, with an age-standardised death rate of 11·5 (11·3-11·8) per 100 000 person-years, which decreased between 1990 and 2017 (-13·5% [-18·4 to -10·0]). Colorectal cancer was also responsible for 19·0 million (18·5-19·5) DALYs globally in 2017, with an age-standardised rate of 235·7 (229·7-242·0) DALYs per 100 000 person-years, which decreased between 1990 and 2017 (-14·5% [-20·4 to -10·3]). Slovakia, the Netherlands, and New Zealand had the highest age-standardised incidence rates in 2017. Greenland, Hungary, and Slovakia had the highest age-standardised death rates in 2017. Numbers of incident cases and deaths were higher among males than females up to the ages of 80-84 years, with the highest rates observed in the oldest age group (≥95 years) for both sexes in 2017. There was a non-linear association between the Socio-demographic Index and the Healthcare Access and Quality Index and age-standardised DALY rates. In 2017, the three largest contributors to DALYs at the global level, for both sexes, were diet low in calcium (20·5% [12·9-28·9]), alcohol use (15·2% [12·1-18·3]), and diet low in milk (14·3% [5·1-24·8]). There is substantial global variation in the burden of colorectal cancer. Although the overall colorectal cancer age-standardised death rate has been decreasing at the global level, the increasing age-standardised incidence rate in most countries poses a major public health challenge across the world. The results of this study could be useful for policy makers to carry out cost-effective interventions and to reduce exposure to modifiable risk factors, particularly in countries with high incidence or increasing burden. Bill & Melinda Gates Foundation.

27 February 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
SRSetareh Rezatabar
Setareh Rezatabar
AKAnsar Karimian
Ansar Karimian
VRVahid Rameshknia
Vahid Rameshknia
HPHadi Parsian
Hadi Parsian
MMMaryam Majidinia
Maryam Majidinia
BYBahman Yousefi
Bahman Yousefi

16 April 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
SDSaber G. Darband
Saber G. Darband
MKMojtaba Kaviani
Mojtaba Kaviani
BYBahman Yousefi
Bahman Yousefi
SSShirin Sadighparvar
Shirin Sadighparvar
FPFirouz G. Pakdel
Firouz G. Pakdel
MMMaryam Majidinia
Maryam Majidinia

25 April 2017 in Journal of Pineal Research
Verified
Journal Article
Open access
PDF file
MMMaryam Majidinia
Maryam Majidinia
ASAlireza Sadeghpour
Alireza Sadeghpour
SMSaeed Mehrzadi
Saeed Mehrzadi
RRRussel J. Reiter
Russel J. Reiter
NKNasrin Khatami
Nasrin Khatami
BYBahman Yousefi
Bahman Yousefi
DNA repair is responsible for maintaining the integrity of the genome. Perturbations in the DNA repair pathways have been identified in several human cancers. Thus, compounds targeting DNA damage response (DDR) hold great promise in cancer therapy. A great deal of effort, in pursuit of new anticancer drugs, has been devoted to understanding the basic mechanisms and functions of the cellular DNA repair machinery. Melatonin, a widely produced indoleamine in all organisms, is associated with a reduced risk of cancer and has multiple regulatory roles on the different aspects of the DDR and DNA repair. Herein, we have mainly discussed how defective components in different DNA repair machineries, including homologous recombination (HR), nonhomologous end‐joining (NHEJ), base excision repair (BER), nucleotide excision repair (NER), and finally DNA mismatch repair (MMR), can contribute to the risk of cancer. Melatonin biosynthesis, mode of action, and antioxidant effects are reviewed along with the means by which the indoleamine regulates DDR at the transduction, mediation, and functional levels. Finally, we summarize recent studies that illustrate how melatonin can be combined with DNA‐damaging agents to improve their efficacy in cancer therapy.

30 January 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
AKAnsar Karimian
Ansar Karimian
KAKhalil Azizian
Khalil Azizian
HPHadi Parsian
Hadi Parsian
SRSona Rafieian
Sona Rafieian
VSVahid Shafiei‐Irannejad
Vahid Shafiei‐Irannejad
BYBahman Yousefi
Bahman Yousefi